<DOC>
	<DOCNO>NCT00656669</DOCNO>
	<brief_summary>The combination paclitaxel , doxorubicin , cyclophosphamide standard neoadjuvant ( give surgery ) treatment patient either inoperable operable breast cancer . This treatment help shrink tumor remove help prevent cancer spread part body . This study do test impact add sunitinib single-agent ( Segment 1 ) , follow sunitinib plus paclitaxel ( Segment 2 ) , follow doxorubicin cyclophosphamide ( Segment 3 ) . We hope addition sunitinib make treatment effective , n't know true .</brief_summary>
	<brief_title>Exploratory Study Sunitinib Malate Component Neoadjuvant Therapy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Patients must histologicallyconfirmed adenocarcinoma breast operable inoperable stage 1c ( primary tumor &gt; 1.0 cm ) , II III disease . 2 . Measurable disease physical examination diagnostic breast imaging ( mammography , ultrasonography MR ) . 3 . Pretreatment core incisional biopsy . Patients may definitive primary surgery . 4 . Male female , 18 year age old . 5 . ECOG performance status 0 1 . 6 . Adequate organ function define protocol . 1 . Prior radiation therapy , cytotoxic therapy systemic therapy breast cancer . Prior use tamoxifen raloxifene chemoprevention allow must discontinue prior study entry . 2 . Metastatic ( Stage IV ) breast cancer 3 . Patients pretreatment fine needle aspiration ( FNA ) exclude . 4 . Current therapeutic treatment another clinical trial investigational agent . 5 . Any follow within 6 month prior start study treatment : myocardial infarction severe/unstable angina coronary/peripheral artery bypass graft congestive heart failure cerebrovascular accident include transient ischemic attack pulmonary embolus 6 . Ongoing cardiac dysrhythmias NCI CTCAE grade &gt; =2 , atrial fibrillation grade , QTc interval &gt; 450 msec male &gt; 470 msec female . 7 . Hypertension control medication . 8 . Current treatment therapeutic dos anticoagulant . Prophylactic use anticoagulant allow . 9 . Known human immunodeficiency virus ( HIV ) infection . 10 . Pregnancy breastfeed . All female patient reproductive potential must negative pregnancy test prior first day study medication . 11 . Other severe acute chronic medical psychiatric condition , laboratory abnormality would impart , judgment investigator , excess risk associate study participation study drug administration , , judgment investigator , would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>newly diagnose breast cancer</keyword>
	<keyword>neoadjuvant therapy</keyword>
</DOC>